Thrombin regulation by physiological inhibitors: The role of vitronectin

Seminars in Thrombosis and Hemostasis

Volumn 22, Issue 2, 1996, Pages 165-172

  Preissner, Klaus T ^a   De Boer, Hetty ^b   Pannekoek, Hans ^c   De Groot, Phillip G ^b  

^a KERCKHOFF HEART CENTER   (Germany)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Endothelial cells; Plasminogen activator inhibitor (PAI 1); Serine protease inhibitors; Thrombin; Vitronectin

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR; SERINE PROTEINASE INHIBITOR; THROMBIN; THROMBOMODULIN; VITRONECTIN;

BLOOD CLOT LYSIS; BLOOD CLOTTING; CONFERENCE PAPER; ENZYME INACTIVATION; FIBRIN CLOT; HUMAN; PRIORITY JOURNAL; THROMBOGENESIS; THROMBOSIS;

EID: 0029977454     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-999005     Document Type: Conference Paper

References (78)

1. Broze GJ, D Gailani: The role of factor XI in coagulation. Thromb Haemostas 70:72-74, 1993.
2. Bar-Shavit R, M Benezra, V Sabbah, W Bode, I Vlodavsky: Thrombin as a multifunctional protein. Induction of cell adhesion and proliferation. Am J Respirai Cell Mol Biol 6:123-130, 1992.
3. Esmon CT: Molecular events that control the protein C anticoagulant pathway. Thromb Haemostas 70:29-35, 1993.
4. Podack ER, HJ Müller-Eberhard: Isolation of human S-protein, an inhibitor of the membrane attack complex of complement. J Biol Chem 254:9908-9914, 1979.
5. Damus PS, M Hicks, RD Rosenberg: A generalized view of heparin's anticoagulant action. Nature 246:335-357, 1973.
6. Villanueva GB, I Danishefsky: Conformational changes accompanying the binding of antithrombin III to thrombin. Biochemistry 18:810-817, 1979.
7. Binder B: On the complex formation of antithrombin III with thrombin. Gelfiltration studies on human plasma and serum. Thromb Diathes Haemorrh 30:280-283, 1973.
8. Marciniak E, G Gora-Maslak: High molecular weight forms of antithrombin III complexes in blood. Thromb Haemostas 49: 32-36, 1983.
9. Preissner KT: Sell-association of antithrombin III relates to multimer formation of thrombin-antithrombin III complexes. Thromb Haemostas 69:422-429, 1993.
10. Pratt CW, FC Church: General features of the heparin binding serpins, antithrombin, heparin cofaclor II and protein C inhibitor. Blood Coag Fibrinolysis 4:479-490, 1993.
11. Griffith MJ: Heparin-catalyzed inhibitor/protease reactions: Kinetic evidence for a common mechanism of action of hecparin. Proc Natl Acad Sci USA 80:5460-5464, 1983.
12. Bourin MC, U Lindahl: Glycosaminoglycans and the regulation of blood coagulation. Biochem J 284:313-330, 1993.
13. Lane DA, R Caso: Antithrombin: Structure, genomic organization, function and inherited deficiency. Bailliere Clin Haematol 2:961-998, 1989.
14. Gloor S, K Odink, J Guenther, H Nick, D Monard: A glia-derived neurite promoting factor with protease inhibitory activity belongs to the protease nexins. Cell 47:687-693, 1986.
15. Church FC, MR Hoffman: Heparin cofactor II and thrombin. Heparin-binding proteins linking hemostasis and inflammation. Trends Cardiovasc Med 4:140-146, 1994.
16. Bar-Shavit R, A Eldor, I Vlodavsky: Binding of thrombin to sub-endothelial extracellular matrix. J Clin Invest 84:1096-1104, 1989.
17. Preissner KT: Physiological role of vessel wall related antithrombotic mechanisms: Contribution of endogenous and exogenous heparin-like components to the anticoagulant potential of the endothelium. Haemostasis 20:30-49, 1990.
18. Zammit A, DS Pepper, J Dawes: Interaction of immobilised unfractionated and low molecular weight heparins with proteins in whole human plasma. Thromb Haemostas 70:951-958, 1993.
19. Lijnen HR, M Hoylaerts, D Collen: Heparin binding properties of human histidine-rich glycoprotein. Mechanism and role in the neutralization of heparin in plasma. J Biol Chem 258:3803-3808. 1983.
20. Lane DA, G Pejler, AM Flynn, EA Thompson, U Lindahl: Neutralization of heparin-related saccharides by histidine-rich glycoprotein and platelet factor 4. J Biol Chem 261:3980-3986, 1986.
21. Preissner KT, G Müller-Berghaus: Neutralisation and binding of heparin by S protein/vitronectin in the inhibition of factor Xa by antithrombin III. Involvement of an inducible heparin binding domain of S protein/vitronectin. J Biol Chem 262:12247:-12253, 1987.
22. Lane DA, AM Flynn, G Pejler, U Lindahl, J Choay, KT Preissner: Structural requirements for the neutralization of heparin-like saccharides by complement S protein/vitronectin. J Biol Chem 262:16343-16349, 1987.
23. Preissner KT, P Sie: S protein neutralizes the anticoagulant activity of glycosaminoglycans in the inhibition of thrombin by heparin cofactor II. (Abst.) Thromb Haemostas 58:227, 1987.
24. Tollefsen DM, CA Pestka: Modulation of heparin cofactor II activity by histidine-rich glycoprotein and platelet factor 4. J Clin Invest 75:496-501, 1985.
25. Suzuki S, MD Pierschbacher, EG Hayman, K Nguyen, Y Ohgren, F Ruoslahti: Domain structure of vitronectin. J Biol Chem 259: 15307-15314, 1984.
26. Preissner KT: The molecular anatomy of vitronectin as extracellular regulator protein: Multifunctional properties of the heparin-binding domain. In: Harenberg J, DL Heene, G Stehle, G Schettler (Eds): New Trends in Haemostasis, Coagulation Proteins, Endotheium, and Tissue Factors. Springer, Heidelberg, Germany. 1990, pp 123-135.
27. Cardin AD, HJR Weintraub: Molecular modeling of protein-glycosaminoglycan interactions. Arteriosclerosis 9:21-31, 1989.
28. Simionescu M, N Simionescu, JE Silbert, GE Palade: Differentiated microdomains on the luminal surface of the capillary endothelium. II. Partial characterization of their anionic sites. J Cell Biol 90:614-621, 1981.
29. Busch C, WG Owen: Identification in vitro of an endothelial cell surface cofactor for antithrombin III-parallel studies with isolated perfused rat hearts and microcarrier cultures of bovine endothelium. J Clin Invest 69:726-729, 1982.
30. Rosenherg RD: Role of heparin and heparinlike molecules in thrombosis and atherosclerosis. Fed Proc 44:404-409, 1985.
31. Saxena U, MG Klein, IJ Goldberg: Identification and characterization of the endothelial-cell surface lipoprotein-lipase receptor. J Biol Chem 266:17516-17521, 1991.
32. Abildgaard U, AK Lindahl, PM Sandset: Heparin requires both antithrombin and extrinsic pathway inhibitor for its anticoagulant effect in human blood. Haemostasis 21:254-257, 1991.
33. Izumi M, KM Yamada, M Hayashi: Vitronectin exists in two structurally and functionally distinct forms in human plasma. Biochim Biophys Acta 990:101-108, 1989.
34. Hess S, A Stockmann, W Völker, KT Preissner: Multimeric vitronectin: Structure and function. In: Preissner KT, S Rosenblatt, J Wegerhoff, C Kost, DF Mosher (Eds): Biology of Vitronectins and Their Receptors. Elsevier, Amsterdam, 1993, pp 21-30.
35. Ill CR, E Ruoslahti: Association of thrombin-antithrombin III complex with vitronectin in serum. J Biol Chem 260:15610-15615, 1985.
36. Jenne D, F Hugo, S Bhakdi: Interaction of complement S-protein with thrombin-antithrombin complexes: A role for the S-protein in haemostasis. Thromb Res 38:401-412, 1985.
37. Preissner KT, L Zwicker, G Müller-Berghaus: Formation, characterization and detection of a ternary complex between S protein, thrombin and antithrombin III in serum. Biochem J 243:105-111, 1987.
38. de Boer HC, PG de Groot, KT Preissner: Metabolism of vitronectin complexes. In: Preissner KT, S Rosenblatt, C Kost, J Wegerhoff, DF Mosher (Eds): Biology of Vitronectins and Their Receptors. Elsevier, Amsterdam, 1993, pp 103-110.
39. Tomasini BR, DF Mosher: Vitronectin. Prog Hemostas Thromb 10:269-305, 1990.
40. Preissner KT: Structure and biological role of vitronectin. Annu Rev Cell Biol 7:275-310, 1991.
41. Tomasini B, DF Mosher: Conformational states of vitronectin: Preferential expression of an antigenic epitope when vitronectin is covalently and noncovalently complexed with thrombin-antithrombin III or treated with urea. Blood 72:903-912, 1988.
42. de Boer HC, PG de Groot, BN Boumu, KT Preissner: Ternary vitronectin-thrombin-antithrombin III complexes in human plasma: Detection and mode of association. J Biol Chem 268:1279-1283, 1993.
43. Stockmann A, S Hess, P Declerck, R Timpl, KT Preissner: Multimeric vitronectin. Identification and characterization of conformation-dependent self-association of the adhesive protein. J Biol Chem 268:22874-22882, 1993.
44. Tomasini BR, DF Mosher, MC Owen, JW Fenton: Conformational lability of vitronectin: Induction of an antigenic change by α-thrombin-serpin complexes and by proteolytically modified thrombin. Biochemistry 28:832-842, 1989.
45. Rovelli G, SR Stone, KT Preissner, D Monard: Specific interaction of vitronectin with the cell-secreted protease inhibitor glia-derived nexin (GDN) and the GDN-thrombin complex. Eur J Biochem 192:797-803, 1990.
46. Preissner KT, E Anders, J Grulich-Henn, G Müller-Berghaus: Attachment of cultured human endothelial cells is promoted by specific association with S protein (vitronectin) as well as with the ternary S protein-thrombin-antithrombin III complex. Blood 71: 1581-1589, 1988.
47. Bar-Shavit R, V Sabbah, MG Lampugnani, PC Marchisio, JW Fenton II, I Vlodavski, E Dejana: An Arg-Gly-Asp sequence within thrombin promotes endothelial cell adhesion. J Cell Biol 112:335-344, 1991.
48. Bar-Shavit R, GD Wilner: Mediation of cellular events by thrombin. Int Rev Exp Pathol 29:213-241, 1986.
49. Kolb WP, LM Kolb: Antithrombin III binding to SC5b-9 attack complexes of human complement: Dissociation of a modified antithrombin III derivative subsequent to complex formation. Biochemistry 22:496-504, 1983.
50. Shifman MA, SV Pizzo: The in vivo metabolism of antithrombin III and anti-thrombin III complexes. J Biol Chem 257:3243-3248, 1982.
51. Fair DS, EF Plow: Specific association of thrombin-antithrombin complexes with a human hepatoma cell line. Thromb Res 41: 67-78, 1986.
52. Perlmutter DH, GI Glover, M Rivetna, CS Schasteen, RJ Fallon: Identification of a serpin-enzyme complex receptor on human hepatoma cells and human monocytes. Proc Natl Acad Sci USA 87:3753-3757, 1990.
53. Joslin G, RJ Fallen, J Bullock, SP Adams, DH Perlmutter: The SEC receptor recognizes a pentapeptide neodomain of α1-antitrypsin-protease complexes. J Biol Chem 266:11282-11288, 1991.
54. Joslin G, GL Griffin, AM August, S Adams, RJ Fallon, RM Senior, DH Perlmutter: The serpin-enzyme complex (SEC) receptor mediates the neutrophil chemotactic effect of al antitrypsin-elastase complexes and amyloid-β peptide. J Clin Invest 90:1150-1154, 1992.
55. de Boer HC, KT Preissner, BN Bouma, PG de Groot: Binding of vitronectin-thrombin-antithrombin III complex to human endothelial cells is mediated by the heparin binding site of vitronectin. J Biol Chem 267:2264-2268, 1992.
56. Elenius K, M Salmivirta, P Inki, M Mali, M Jalkanen: Binding of human syndecan to extracellular-matrix proteins. J Biol Chem 265:17837-17843, 1990.
57. Mertens G, JJ Cassiman, H Van den Berghe, J Vermylen, G David: Cell surface heparan sulfate proteoglycans from human vascular endothelial cells. Core protein characterization and antithrombin III binding properties. J Biol Chem 267:20435-20443, 1992.
58. Krieger M, S Acton, J Ashkenas, A Pearson, M Penman, D Resnick: Molecular flypaper, host defense, and atherosclerosis. Structure, binding properties, and functions of macrophage scavanger receptors. J Biol Chem 268:4569-4572, 1993.
59. Guettier C, N Hinglais, P Bruneval, M Kazatchkine, J Bariety, J-P Camilleri: Immunohistochemical localization of S protein/vitronectin in human atherosclerotic versus arteriosclerotic arteries. Virchows Arch A Pathol Anat 414:309-313, 1989.
60. Reilly JT, JRG Nash: Vitronectin (serum spreading factor): Its localisation in normal and fibrotic tissue. J Clin Pathol 41:1269-1272, 1988.
61. Preissner KT, D Jenne: Vitronectin: A new molecular connection in haemostasis. Thromb Haemostas 66:189-194, 1991.
62. Declerck PJ, M De Mol, M-C Alessi, S Baudner, E-P Paques, KT Preissner, G Müller-Berghaus, D Collen: Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin). J Biol Chem 263:15454-15461, 1988.
63. Wiman B, A Almquist, O Sigurdardottir, T Lindahl: Plasminogen-activator inhibitor-1 (PAI) is bound to vitronectin in plasma. FEBS Lett 242:125-128, 1988.
64. Mimuro J, DJ Loskutoff: Purification of a protein from bovine plasma that binds to type-1 plasminogen-activator inhibitor and prevents its interaction with extracellular-matrix - evidence that the protein is vitronectin. J Biol Chem 264:936-939, 1989.
65. Preissner KT, J Grulich-Henn, HJ Ehrlich, P Declerck, C Justus, D Collen, H Pannekoek, G Müller-Berghaus: Structural requirements for the extracellular interaction of plasminogen activator inhibitor 1 with endothelial cell matrix-associated vitronectin. J Biol Chem 265:18490-18498, 1990.
66. Grulich-Henn J, G Müller-Berghaus, KT Preissner: The influence of growth substratum and cell activation on the deposition of plasminogen activator inhibitor-1 in the extracellular matrix of human endothelial cells. Fibrinolysis 6(Suppl 4):131-137, 1992.
67. Salonen E-M, A Vaheri, J Pöllänen, R Stephens, P Andreasen, M Mayer, K Dano, J Gailit, E Ruoslahti: Interaction of plasminogen activator inhibitor (PAI-1) with vitronectin. J Biol Chem 264: 6339-6343, 1989.
68. Preissner KT, S Holzhüter, C Justus, G Müller-Berghaus: Identification and partial characterization of platelet vitronectin: Evidence for complex formation with platelet-derived plasminogen activator inhibitor-1. Blood 74:1989-1996, 1989.
69. Stringer HAR, P van Swieten, HFG Heijnen, JJ Sixma, H Pannekoek: Plasminogen activator inhibitor-1 released from activated platelets plays a key role in thrombolytic resistance. Studies with thrombi generated in the Chandler loop. Arterioscler Thromb 14: 1452-1458, 1994.
70. Levi M, BJ Biemond, A-J van Zonneveld, JW ten Cate, H Pannekoek: Inhibition of plasminogen activator inhibitor-1 activity results in promotion of endogenous thrombolysis and inhibition of thrombin extension in models of experimental thrombosis. Circulation 85:305-312, 1992.
71. Ehrlich HJ, J Keijer, KT Preissner, R Klein Gebbink, H Pannekoek: Functional interaction of plasminogen activator inhibitor type 1 (PAI-1) and heparin. Biochemistry 30:1021-1028, 1991.
72. Ehrlich HJ, R Klein Gebbink, J Keijer, M Linders, KT Preissner, H Pannekoek: Alteration of serpin specificity by a protein cofactor. Vitronectin endows plasminogen activator inhibitor 1 with thrombin inhibitory properties. J Biol Chem 265:13029-13035, 1990.
73. Ehrlich HJ, R Klein Gebbink, KT Preissner, J Keijer, NL Esmon, K Mertens, H Pannekoek: Thrombin neutralizes plasminogen activator inhibitor 1 (PAI-1) that is complexed with vitronectin in the endothelial cell matrix. J Cell Biol 115:1773-1781, 1991.
74. van den Nieuwenhuizen M, AJ van Zonneveld, H Pannekoek: On the mechanism of interaction between PAI-1 and either t-PA or thrombin: The effect of vitronectin. Thromb Haemostas 69:771, 1993.
75. Olson D, J Pöllänen, G Hoyers-Hansen, E Ronne, K Sakaguchi, TC Wun, E Appella, K Dano, F Blasi: Internalization of the urokinase plasminogen activator inhibitor type-1 complex is mediated by the urokinase receptor. J Biol Chem 267:9129-9133, 1992.
76. Andreasen PA, L Sottrup-Jensen, L Kjoller, A Nykjaer, SK Moestrup, CM Petersen, J Gliemann: Receptor-mediated endocytosis of plasminogen activators and activator/inhibitor complexes. FEBS Lett 338:239-245, 1994.
77. Bu G, S Williams, DK Strickland, AL Schwartz: Low density lipoprotein receptor related protein/α2-maeroglobulin receptor is a hepatic receptor for tissue-type plasminogen activator. Proc Natl Acad Sci USA 89:7427-7431, 1992.
78. Orth K, LE Madison, M Gething, JF Sambrook, J Herz: Complexes of tissue-type plasminogen activator with PAI-1 are internalized by means of the low density lipoprotein receptor-related protein/α2-macroglobulin receptor. Proc Natl Acad Sci USA 89:7422-7426, 1992.